Department of Psychiatry, Weill Cornell Medicine/New York Presbyterian, NY, New York, USA.
CUNY Graduate School of Public Health, New York, NY, USA.
Res Child Adolesc Psychopathol. 2022 Sep;50(9):1107-1119. doi: 10.1007/s10802-022-00919-z. Epub 2022 Apr 20.
Group programs are key for targeting social skills (SS) for children with developmental disorders and/or mental illness. Despite promising evidence regarding efficacy of group treatments, there are several limitations to current research regarding generalizability and effectiveness across diagnoses. This randomized control trial assessed whether the Secret Agent Society (SAS) group program was superior to treatment as usual (TAU) in improving social-emotional functioning for children with Attention Deficit-Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), and/or anxiety. Eighty-nine youth (8-12) with ADHD, ASD, and/or an anxiety disorder receiving treatment at hospital-based outpatient clinics were randomized to receive SAS (n = 47) or TAU (n = 42) over a three-month period, at which point TAU participants were offered the SAS intervention. Parent report showed significant improvement in Emotion Regulation (ER) and Social Skills (SS) for youth in SAS vs. TAU (Fs ≥ 6.79, ps ≤ 01). Gains for the SAS condition were maintained at 6-months. Intent-to-treat analysis of teacher report indicated youth in SAS had positive gains in SS (F = 0.41, p = 0.475) and ER (F = 0.99, p = 0.322), though not significantly better than youth in TAU. Clinically reliable improvement rates were significantly higher for SAS participants than TAU for parent and teacher reported SS and ER. Improvements were significant for youth with single and comorbid diagnoses. Results suggest that SAS was superior to TAU in improving SS and ER for youth aged 8-12 with ADHD, ASD, and/or anxiety. Gains maintained in the medium-term. Trial registration number NCT02574273, registered 10/12/2015.
团体项目是针对发育障碍和/或精神疾病儿童社交技能的关键。尽管团体治疗的疗效有令人鼓舞的证据,但目前关于诊断间通用性和有效性的研究存在几个局限性。这项随机对照试验评估了秘密特工协会(SAS)团体计划是否优于常规治疗(TAU),以改善患有注意力缺陷多动障碍(ADHD)、自闭症谱系障碍(ASD)和/或焦虑症的儿童的社会情感功能。89 名(8-12 岁)在医院门诊接受治疗的患有 ADHD、ASD 和/或焦虑症的青少年被随机分配接受 SAS(n=47)或 TAU(n=42)治疗,为期三个月,此时 TAU 参与者被提供 SAS 干预。父母报告显示,SAS 组青少年的情绪调节(ER)和社交技能(SS)有显著改善,而 TAU 组(Fs≥6.79,ps≤01)。SAS 组的收益在 6 个月时保持不变。对教师报告的意向性治疗分析表明,SAS 组的青少年在 SS(F=0.41,p=0.475)和 ER(F=0.99,p=0.322)方面有积极的收益,但并不显著优于 TAU 组的青少年。SAS 组的临床可靠改善率明显高于 TAU 组,无论是在父母还是教师报告的 SS 和 ER 方面。对于患有单一和共病诊断的青少年,改善效果显著。结果表明,SAS 在改善 8-12 岁患有 ADHD、ASD 和/或焦虑症的青少年的 SS 和 ER 方面优于 TAU。中期收益保持。试验注册号 NCT02574273,于 2015 年 10 月 12 日注册。